ICCM - IceCure's ProSense System to freeze tumors submitted for regulatory approval in Brazil

IceCure Medical (NASDAQ:ICCM) on Thursday said its Brazilian distributor KTRFIOS had submitted a regulatory filing to the country's drug regulator for approval of ICCM's ProSense System in several indications. ICCM's ProSense System destroys tumors by freezing, providing an alternative to surgical removal. The filing includes breast and other cancers, benign tumors, palliative intervention, and other indications. The filing is part of KTRFIOS' agreement with ICCM which also includes KTRFIOS' guarantee of at least $6.6M in total sales for five years following regulatory approval.

For further details see:

IceCure's ProSense System to freeze tumors submitted for regulatory approval in Brazil